Clinical Scorecard: Prevalence and Risk Factors of Rifampicin-Resistant Tuberculosis in Nangarhar, Afghanistan

At a Glance

Key Highlights

• Facility-based prevalence of RR-TB estimated using routine Xpert MTB/RIF data from three major centres.
• Independent risk factors identified through a case–control study with contemporaneous rifampin-susceptible controls.
• Phenotypic resistance patterns described among rifampicin-resistant cases to inform targeted interventions.

Guideline-Based Recommendations

Diagnosis

• Use Xpert MTB/RIF molecular testing for rapid detection of rifampin resistance in presumptive pulmonary TB patients.
• Classify TB cases as new or previously treated per WHO definitions to assess risk profiles.

Management

• Implement programmatic management of drug-resistant TB with consideration of local resistance patterns.
• Prioritize household- and facility-level interventions to interrupt transmission in high-density living conditions.

Monitoring & Follow-up

• Conduct phenotypic drug susceptibility testing for first- and second-line drugs among RR-TB cases.
• Maintain contemporaneous and comparable control groups for ongoing surveillance and risk factor analysis.

Risks

• Recognize previous TB treatment, close or prolonged exposure to infectious cases, and household crowding as key risk factors for RR-TB.
• Address health system constraints and population displacement that complicate continuity of care and infection control.

Patient & Prescribing Data

Adults ≥ 15 years with Xpert-confirmed pulmonary TB in Nangarhar Province

Rifampin resistance detected by Xpert MTB/RIF guides treatment decisions; phenotypic DST informs appropriate first- and second-line drug use.

Clinical Best Practices

• Enroll RR-TB cases consecutively and select rifampin-susceptible controls randomly and contemporaneously to ensure valid risk factor analysis.
• Use structured, culturally adapted questionnaires administered by trained clinicians blinded to resistance status to minimize bias.
• Follow WHO and Global Laboratory Initiative guidelines for laboratory and clinical procedures in TB diagnosis and management.

References

• WHO End TB Strategy
• Global Tuberculosis Report 2023
• Programmatic Management of Drug-Resistant TB in Kandahar, Afghanistan
• Risk Factors for MDR/RR-TB: Systematic Reviews
• STROBE Guidelines for Observational Studies
• WHO Definitions for TB Case Categories
• Global Laboratory Initiative (GLI) Guidance